Egypt clears Chinese Sinovac vaccine for use for emergency use

Egyptian Health regulators have granted approval to China’s Sinovac vaccine for emergency use, the authority said in a statement last night.

This is the fourth covid vaccine approved by the EDA following Sinopharm, Oxford / AstraZeneca, and Russia’s Sputnik V.

Last week, the Egyptian Holding Company for Biopharmaceuticals and Vaccines (Vacsera) signed two agreements with China’s Sinovac Life Sciences Company to manufacture the Chinese vaccine in Egypt.

Sinovac has an efficacy rate of 50.4 percent in preventing infections — well below the 92 percent efficacy rate boasted by Sputnik V, the 79% reported by Sinopharm, and 76% by AstraZeneca.